Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody
Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development.
The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections.
Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.'
BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise.
MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025.
The full publication can be accessed here.
-Ends-
Contacts
Memo Therapeutics AG
info@memo-therapeutics.com
ICR Healthcare
Amber Fennell, Ashley Tapp
memotx@icrhealthcare.com
+44 (0)20 3709 5700
About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn.
Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at www.memo-therapeutics.com, and on LinkedIn.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. Read On The Fox News App This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. Ancient 'Pharaoh's Curse' Fungus Shows Promise In Killing Cancer Cells "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. Click Here To Sign Up For Our Health Newsletter "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. For more Health articles, visit "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for article source: Common sweetener could hold untapped potential to fight aggressive cancer, study finds Solve the daily Crossword
Fox News
a day ago
- Fox News
Common sweetener could hold untapped potential to fight aggressive cancer, study finds
A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for comment.
Yahoo
3 days ago
- Yahoo
Rhino horns turned radioactive to fight poachers in South Africa
South African scientists have launched an anti-poaching campaign in which rhino's horns will be injected with a radioactive material. The group, from the University of the Witwatersrand, said the process is harmless to rhinos but will allow customs officers to detect smuggled horns as they're transported across the world. South Africa has the largest rhino population in the world, and hundreds of the animals are poached there every year. The university's venture, called the Rhisotope Project, was launched on Friday after six years of research and testing. "Our goal is to deploy the Rhisotope technology at scale to help protect one of Africa's most iconic and threatened species," said Jessica Babich, head of the Rhisotope Project. "By doing so, we safeguard not just rhinos but a vital part of our natural heritage." Tests conducted in the pilot study, which involved 20 rhinos, confirmed that the radioactive material was not harmful to the animals. "We have demonstrated, beyond scientific doubt, that the process is completely safe for the animal and effective in making the horn detectable through international customs nuclear security systems," said James Larkin a professor at Wits University who is also part of the project. The horns of African rhinos are often exported to Asian markets were they are used in traditional medicine and also seen as a status symbol. White rhinos are considered threatened, while black rhinos are critically endangered. You may also be interested in: World's first IVF rhino pregnancy 'could save species' Illegal trade booms in South Africa's 'super-strange looking' plants PODCAST: Women in South Africa and Zambia protect wildlife from poachers Go to for more news from the African continent. Follow us on Twitter @BBCAfrica, on Facebook at BBC Africa or on Instagram at bbcafrica BBC Africa podcasts Africa Daily Focus on Africa
